Aurobindo Pharma recalls 22 lots of Irbesartan over cancer risk

Aurobindo Pharma issued a voluntary recall of 22 batches of Irbesartan, a drug used in the treatment of hypertension, due to the presence of an impurity linked to cancer, according to

The impurity is known as N-nitrosodiethylamine, classified as a probable human carcinogen.

The 22 batches were supplied to ScieGen Pharmaceuticals for manufacturing finished Irbesartan tablets in the U.S.

The affected lots, manufactured by ScieGen, have been labeled as Westminster Pharmaceuticals and Golden State Medical Supply. The 75-milligram, 150-milligram and 300-milligram tablets are part of the recall.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars